News | July 05, 2023
Biocon Biologics expands footprint in emerging markets
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing
Subscribe To Our Newsletter & Stay Updated
